Stéphane Leprêtre Selected Research

B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

12/2022	5' Rapid amplification of cDNA ends (5'RACE): A simpler method to analyze immunoglobulin genes and discover the value of the light chain in chronic lymphocytic leukemia.
6/2022	Therapy-related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Who Received FCR/FC as Frontline Therapy.
1/2022	The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition.
1/2022	miRNA profile at diagnosis predicts treatment outcome in patients with B-chronic lymphocytic leukemia: A FILO study.
1/2020	Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.
1/2019	Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study.
1/2018	Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study.
1/2018	Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.
1/2017	Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.
1/2017	Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stéphane Leprêtre Research Topics

Disease

15	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2022 - 06/2011
6	Neoplasms (Cancer) 02/2023 - 05/2015
4	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 07/2022 - 01/2018
4	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2020 - 09/2015
3	Infections 07/2022 - 05/2015
2	Residual Neoplasm 01/2022 - 03/2012
2	Leukemia 10/2020 - 11/2018
2	Philadelphia Chromosome 01/2020 - 09/2015
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2019 - 08/2017
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 06/2015 - 05/2013
2	Sarcopenia 07/2014 - 04/2014
1	Inflammation (Inflammations) 07/2023
1	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 06/2023
1	T-Cell Lymphoma (Lymphoma, T Cell) 06/2023
1	Lymphoma (Lymphomas) 06/2023
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 02/2023
1	Pathologic Complete Response 01/2023
1	Immunoglobulin Light-chain Amyloidosis 01/2023
1	Anemia 01/2023
1	Cryoglobulinemia 01/2023
1	Chronic Disease (Chronic Diseases) 01/2023
1	Myocardial Ischemia (Ischemic Heart Diseases) 12/2022
1	Heart Valve Diseases (Valvular Heart Disease) 12/2022
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/2022
1	Venous Thrombosis (Deep-Vein Thrombosis) 07/2022
1	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 01/2022
1	Rheumatoid Arthritis 01/2022
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2022
1	Waldenstrom Macroglobulinemia (Macroglobulinemia) 11/2021
1	Trisomy (Trisomies) 01/2020
1	Neutropenia 02/2018
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2018
1	Hypersensitivity (Allergy) 09/2015
1	Pancreatitis 09/2015
1	Febrile Neutropenia 05/2015
1	Cachexia 07/2014
1	Sepsis (Septicemia) 06/2014
1	Peritonitis 06/2014
1	Limbic Encephalitis (Paraneoplastic Limbic Encephalitis) 05/2013

Drug/Important Bio-Agent (IBA)

15	Rituximab (Mabthera)FDA Link 02/2023 - 03/2012
6	fludarabineIBA 01/2023 - 02/2016
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2023 - 02/2016
3	Biomarkers (Surrogate Marker)IBA 12/2022 - 01/2017
2	obinutuzumabIBA 01/2023 - 11/2021
2	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 12/2022 - 11/2018
2	Monoclonal AntibodiesIBA 01/2022 - 01/2017
2	Asparaginase (Elspar)FDA Link 01/2019 - 09/2015
2	Alemtuzumab (Campath)FDA Link 01/2018 - 03/2012
1	Prealbumin (Transthyretin)IBA 07/2023
1	belinostatIBA 06/2023
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 02/2023
1	ibrutinibIBA 01/2023
1	Immunoglobulin M (IgM)IBA 01/2023
1	AntibodiesIBA 01/2023
1	Proteins (Proteins, Gene)FDA Link 01/2023
1	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2022
1	AnthracyclinesIBA 12/2022
1	Complementary DNA (cDNA)IBA 12/2022
1	AntigensIBA 01/2022
1	MicroRNAs (MicroRNA)IBA 01/2022
1	idelalisibIBA 11/2021
1	ponatinibIBA 01/2020
1	Thymidine KinaseIBA 01/2020
1	Aspartate-Ammonia Ligase (Asparagine Synthetase)IBA 01/2019
1	DNA (Deoxyribonucleic Acid)IBA 01/2019
1	Cell-Free Nucleic AcidsIBA 01/2018
1	Cytokine Receptors (Cytokine Receptor)IBA 08/2017
1	Histones (Histone)IBA 08/2017
1	CD20 AntigensIBA 01/2017
1	RNA (Ribonucleic Acid)IBA 01/2017
1	Lipase (Acid Lipase)FDA Link 09/2015
1	Cytarabine (Cytosar-U)FDA LinkGeneric 08/2015
1	PlatinumIBA 08/2015
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 06/2015
1	Transcription Factors (Transcription Factor)IBA 06/2015
1	Dasatinib (BMS 354825)FDA Link 06/2015
1	Core Binding Factors (Core-Binding Factor)IBA 06/2015
1	Fluorine-18IBA 05/2015
1	Voltage-Gated Potassium Channels (Voltage-Gated Potassium Channel)IBA 05/2013
1	Purine NucleosidesIBA 03/2012

Therapy/Procedure

7	Therapeutics 06/2023 - 06/2015
5	Drug Therapy (Chemotherapy) 12/2022 - 04/2014
2	Stem Cell Transplantation 06/2023 - 06/2011
2	Immunotherapy 01/2022 - 03/2012
1	Catheters 07/2022
1	Vascular Access Devices (Arterial Line) 07/2022
1	Central Venous Catheters 05/2015